| |
NewswireToday - /newswire/ -
North Andover, MA, United States, 10/04/2010 - Kollodis BioSciences announced today the expansion of its ECM product line to address the needs of the emerging stem cell culture market.
|
| |
Following 2009's successful launch of the MAPTrix™ ECM product line into the general cell culture market, Kollodis BioSciences announced today the expansion of its ECM product line to address the needs of the emerging stem cell culture market.
Construction of a proprietary library (MAPTrix™ ECM Library) comprised of mussel adhesive protein based extracellular matrix mimetics will strengthen Kollodis BioSciences’ market position in the growing stem cell market.
The MAPTrix™ ECM Library is currently comprised peptide mimetics derived from fibronectin, laminin, collagen, vitronectin, nidogen, cadherin, perlecan, and Tenascin- all of which are main ingredients for a basement membrane.
“The MAPTrix™ ECM Library clearly offers a convenient tool for scientists to screen an optimal ECM-derived peptide composition in order to design or create a user-defined cell growth surface. Unlike existing products derived from animal components, MAPTrix™ ECM provides a biochemically well-defined surface for cell cultures”, said Louis M. Scarmoutzos, Ph.D., Chief Executive Officer and President of Kollodis BioSciences.
The offer of ECM-derived peptide compositions to create a customized artificial basement membrane is a global first.
“We believe MAPTrix™ ECM defined substrates provide a breakthrough solution in overcoming several existing market challenges including animal-component free & chemically defined surfaces”, added Louis M. Scarmoutzos, Ph.D., Chief Executive Officer and President of Kollodis BioSciences.
Since MAPTrix™ ECM itself contains a variety of extracellular matrix derived peptides such as RGD or YIGSR, MAPTrix™ ECM based substrates provide a suitable in vivo like environment for cells that require attachment sites. Unlike existing synthetic substrate products, no additional ECM components are required to create an in vivo like environment.
About Kollodis BioSciences, Inc.
Kollodis BioSciences, Inc. (kollodis.com) has successfully developed a proprietary recombinant protein expression system for the large scale production of various mussel adhesive proteins (MAP). Kollodis is dedicated to the development, manufacture, and sale of MAP-based smart biomaterials for biotech, medical and industrial applications. The Company's proprietary and patented MAPTrix™ platform technology recombinantly incorporates bioactive peptides into a mussel adhesive protein (MAP) for cell culture and related applications.
|
info[.]kollodis.com 
